Christopher R. Chitambar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher R. Chitambar has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Adam Currey
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
21 shared publications - Alexis Vistocky
Division of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin
21 shared publications - Anjishnu Banerjee
Department of Biostatistics, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
21 shared publications - Aronne M. Schottstaedt
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin
21 shared publications - Carmen Bergom
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
21 shared publications - Gopika SenthilKumar
Medical Scientist Training Program, Medical College of Wisconsin, Milwaukee, Wisconsin
21 shared publications
Latest Publications
- 8 May 2026
- Published by Elsevier in Pharmacological Reviews
- Vol. 78 (4) , 100138
Reharnessing the therapeutic potential of gallium-based compounds in oncology: From the laboratory to the clinic
- 8 May 2026
- Published by Elsevier in Pharmacological Reviews
- Vol. 78 (4) , 100138
Reharnessing the therapeutic potential of gallium-based compounds in oncology: From the laboratory to the clinic
- Open Access
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdag154
A phase 1 trial of iron metabolism-targeting oral gallium maltolate in recurrent and refractory glioblastoma
Background: Gallium maltolate is an oral compound that disrupts iron-dependent glioblastoma (GBM) growth and prolongs survival in animal models. This Phase 1 trial of oral gallium maltolate in patients with recurrent GBM was conducted to assess toxicity, determine a recommended Phase 2 dose (RP2D), and seek signals of tumor response. Methods: Using a 3 + 3 dose-escalation design with 5 drug dose levels of oral gallium maltolate (500-2,500 mg daily), 24 patients received a minimum of one 4-week cycle to assess toxicity, and 22 of these patients received a minimum of 2 cycles to assess tumor response. Patients with stable disease on MRI at 8 weeks continued treatment until progression. Results: Grade 1 or 2 adverse effects of diarrhea, anorexia, nausea, and fatigue occurred in 24 patients. The RP2D was determined by considering diarrhea requiring treatment and serum gallium levels that plateaued at doses of 2,000-2,500 mg/day. ALT elevation occurred in 1 patient each on 1,000 and 2,000 mg/day. RBC MCV decreased below normal during treatment in 9 patients. Nephrotoxicity was not seen. GBM progressed in 11 of 22 evaluable patients after 2 cycles and in 6 following 3-6 cycles. Three patients progressed after 8, 10, and 26 cycles. One patient with a stable partial response remains on treatment after 33 cycles. The median overall survival was 16 months. Conclusions: Oral gallium maltolate is safe and well-tolerated with an RP2D of 2,000 mg/day. Further investigation to assess the clinical efficacy of gallium maltolate in GBM is warranted.
- 12 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdag154
Open AccessA phase 1 trial of iron metabolism-targeting oral gallium maltolate in recurrent and refractory glioblastoma
Background: Gallium maltolate is an oral compound that disrupts iron-dependent glioblastoma (GBM) growth and prolongs survival in animal models. This Phase 1 trial of oral gallium maltolate in patients with recurrent GBM was conducted to assess toxicity, determine a recommended Phase 2 dose (RP2D), and seek signals of tumor response. Methods: Using a 3 + 3 dose-escalation design with 5 drug dose levels of oral gallium maltolate (500-2,500 mg daily), 24 patients received a minimum of one 4-week cycle to assess toxicity, and 22 of these patients received a minimum of 2 cycles to assess tumor response. Patients with stable disease on MRI at 8 weeks continued treatment until progression. Results: Grade 1 or 2 adverse effects of diarrhea, anorexia, nausea, and fatigue occurred in 24 patients. The RP2D was determined by considering diarrhea requiring treatment and serum gallium levels that plateaued at doses of 2,000-2,500 mg/day. ALT elevation occurred in 1 patient each on 1,000 and 2,000 mg/day. RBC MCV decreased below normal during treatment in 9 patients. Nephrotoxicity was not seen. GBM progressed in 11 of 22 evaluable patients after 2 cycles and in 6 following 3-6 cycles. Three patients progressed after 8, 10, and 26 cycles. One patient with a stable partial response remains on treatment after 33 cycles. The median overall survival was 16 months. Conclusions: Oral gallium maltolate is safe and well-tolerated with an RP2D of 2,000 mg/day. Further investigation to assess the clinical efficacy of gallium maltolate in GBM is warranted.
- Open Access
- 7 May 2024
- Published by American Association for Cancer Research (AACR)
TABLE 5 from Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
Comparisons of cytokine levels at baseline, 3 months, and 6 months
- 7 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 5 from Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
Comparisons of cytokine levels at baseline, 3 months, and 6 months
- Open Access
- 7 May 2024
- Published by American Association for Cancer Research (AACR)
TABLE 5 from Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
Comparisons of cytokine levels at baseline, 3 months, and 6 months
- 7 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 5 from Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
Comparisons of cytokine levels at baseline, 3 months, and 6 months
- Open Access
- 7 May 2024
- Published by American Association for Cancer Research (AACR)
TABLE 4 from Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
Comparisons of resting metabolism and energy expenditure, and metabolic biomarkers at baseline, 3 months, and 6 months
- 7 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 4 from Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
Comparisons of resting metabolism and energy expenditure, and metabolic biomarkers at baseline, 3 months, and 6 months
- Open Access
- 7 May 2024
- Published by American Association for Cancer Research (AACR)
TABLE 4 from Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
Comparisons of resting metabolism and energy expenditure, and metabolic biomarkers at baseline, 3 months, and 6 months
- 7 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 4 from Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
Comparisons of resting metabolism and energy expenditure, and metabolic biomarkers at baseline, 3 months, and 6 months
- Open Access
- 7 May 2024
- Published by American Association for Cancer Research (AACR)
Data from Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
Purpose:Among patients with breast cancer undergoing radiotherapy, posttreatment cardiovascular disease and worsened quality of life (QoL) are leading causes of morbidity and mortality. To overcome these negative radiotherapy effects, this prospective, randomized clinical trial pilots a 12-week Stay on Track exercise and diet intervention for overweight patients with nonmetastatic breast cancer undergoing whole-breast radiotherapy.Experimental Design:The intervention group (n = 22) participated in three personal exercise and dietary counseling sessions, and received three text reminders/week to adhere to recommendations. The control group (n = 22) was administered a diet/exercise information binder. All patients received a Fitbit, and at baseline, 3 months, and 6 months, measurements of biomarkers, dual-energy X-ray absorptiometry scans, QoL and physical activity surveys, and food frequency questionnaires were obtained. A satisfaction survey was administered at 3 months.Results:Stay on Track was well received, with high rates of adherence and satisfaction. The intervention group showed an increase in self-reported physical activity and preserved QoL, a decrease in body mass index and visceral fat, and higher American Cancer Society/American Institute of Cancer Research dietary adherence. The control participants had reduced QoL, anti-inflammatory markers, and increased metabolic syndrome markers. Both groups had decreased overall body mass. These changes were within group effects. When comparing the intervention and control groups over time, there were notable improvements in dietary adherence in the intervention group.Conclusions:Targeted lifestyle interventions during radiotherapy are feasible and could decrease cardiovascular comorbidities in patients with breast cancer. Larger-scale implementation with longer follow-up can better determine interventions that influence cardiometabolic health and QoL.Significance:This pilot study examines cardiometabolic benefits of a combined diet and exercise intervention for patients with breast cancer undergoing radiotherapy. The intervention included an activity tracker (FitBit) and text message reminders to promote adherence to lifestyle interventions. Large-scale implementation of such programs may improve cardiometabolic outcomes and overall QoL among patients with breast cancer.
- 7 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
Purpose:Among patients with breast cancer undergoing radiotherapy, posttreatment cardiovascular disease and worsened quality of life (QoL) are leading causes of morbidity and mortality. To overcome these negative radiotherapy effects, this prospective, randomized clinical trial pilots a 12-week Stay on Track exercise and diet intervention for overweight patients with nonmetastatic breast cancer undergoing whole-breast radiotherapy.Experimental Design:The intervention group (n = 22) participated in three personal exercise and dietary counseling sessions, and received three text reminders/week to adhere to recommendations. The control group (n = 22) was administered a diet/exercise information binder. All patients received a Fitbit, and at baseline, 3 months, and 6 months, measurements of biomarkers, dual-energy X-ray absorptiometry scans, QoL and physical activity surveys, and food frequency questionnaires were obtained. A satisfaction survey was administered at 3 months.Results:Stay on Track was well received, with high rates of adherence and satisfaction. The intervention group showed an increase in self-reported physical activity and preserved QoL, a decrease in body mass index and visceral fat, and higher American Cancer Society/American Institute of Cancer Research dietary adherence. The control participants had reduced QoL, anti-inflammatory markers, and increased metabolic syndrome markers. Both groups had decreased overall body mass. These changes were within group effects. When comparing the intervention and control groups over time, there were notable improvements in dietary adherence in the intervention group.Conclusions:Targeted lifestyle interventions during radiotherapy are feasible and could decrease cardiovascular comorbidities in patients with breast cancer. Larger-scale implementation with longer follow-up can better determine interventions that influence cardiometabolic health and QoL.Significance:This pilot study examines cardiometabolic benefits of a combined diet and exercise intervention for patients with breast cancer undergoing radiotherapy. The intervention included an activity tracker (FitBit) and text message reminders to promote adherence to lifestyle interventions. Large-scale implementation of such programs may improve cardiometabolic outcomes and overall QoL among patients with breast cancer.
- Open Access
- 7 May 2024
- Published by American Association for Cancer Research (AACR)
TABLE 2 from Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
QoL measures and patient-reported physical activity at baseline, 3 months, and 6 months
- 7 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 2 from Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
QoL measures and patient-reported physical activity at baseline, 3 months, and 6 months
- Open Access
- 7 May 2024
- Published by American Association for Cancer Research (AACR)
TABLE 3 from Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
Body composition and DEXA scan analysis at baseline, 3 months, and 6 months
- 7 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 3 from Stay on Track: A Pilot Randomized Control Trial on the Feasibility of a Diet and Exercise Intervention in Patients with Breast Cancer Receiving Radiotherapy
Body composition and DEXA scan analysis at baseline, 3 months, and 6 months